4Bio Capital

4BIO Capital is a London-based venture capital firm specializing in advanced therapies, particularly in areas like gene therapy, cell therapy, RNA-based treatments, and the microbiome. The firm is focused on addressing high unmet medical and social needs through early-stage investments in innovative life sciences companies. Founded by a team of experienced academics, physician-scientists, and industry executives, 4BIO Capital has built a strong reputation for its deep expertise in the rapidly evolving field of advanced therapies. The firm’s strategy involves not only backing early-stage startups but also creating new companies by leveraging cutting-edge research from academic institutions across Europe and the U.K. 4BIO Capital recently raised $50 million for its second advanced therapy VC fund, with plans to increase this to $150 million. This fund is dedicated to expanding the use of advanced therapies beyond rare diseases to treat more prevalent conditions like diabetes and rheumatoid arthritis. The firm has a global investment focus, with no geographical restrictions, though it emphasizes the untapped potential within U.K. institutions. The team at 4BIO includes managing partners Dmitry Kuzmin and Andrew Kozlov, who bring a wealth of knowledge and experience in life sciences and venture investing, helping to drive the firm’s mission of bringing transformative therapies to market​.